• search
For Quick Alerts
ALLOW NOTIFICATIONS  
For Daily Alerts

WHO's decision to resume HCQ clinical trial a step in right direction, say experts

By PTI
|

New Delhi, June 04: Terming WHO's decision to resume testing of hydroxychloroquine as a potential treatment for COVID-19 in its global clinical trial "a step in the right direction", experts said any "positive outcome" of the exercise will be in the larger interest of the people globally.

WHOs decision to resume HCQ clinical trial a step in right direction, say experts

The global heath body had earlier suspended the hydroxychloroquine (HCQ) arm of the clinical trials of experimental COVID-19 drugs over safety concerns. However on Wednesday, it recommended the trial to be continued following a review of safety data.

    Vijay Mallya may not be extradietd to India soon, another legal hurdle in way | Oneindia News

    Controversial Lancet study linking HCQ, deaths in COVID-19 treatment retracted

    "On the basis of the available mortality data... the members of the Solidarity Data Safety Monitoring Committee unanimously agreed that there are no cogent reasons to recommend modifications of the protocol of the trail and advised that the trial should be continued as planned," the Executive Group of the Steering Committee of the Solidarity Trial wrote to all National Principal Investigators of the Solidarity Trial.

    Welcoming WHO's decision, ICMR Director General Dr Balram Bhargava said, "ICMR and India have been firm on recommendations about the drug based on biological plausibility, in vitro data and case controlled studies. "It is a time tested drug in use for decades. Any positive outcome from the clinical exercise will be in the larger interest of the people globally." He had earlier said that no major side-effects of the anti-malarial drug hydroxychloroquine has been found in studies in India and its use can be continued as prophylaxis for COVID-19 under strict medical supervision. AIIMS Director Randeep Guleria said WHO's decision about resuming the HCQ arm of the clinical trial was "a step in the right direction towards larger public interest".

    "Data from India both from AIIMS and ICMR shows a good safety profile. We did not find that this drug was causing significant cardiac toxicity and therefore it is good that WHO reviewed their data and reintroduced the drug in the trial. "This is a drug which is less expensive, easily available and has been used widely for a long time with good safety data. It will be good if the medicine turns out be beneficial in some way in COVID-19 treatment," he said.

    Coronavirus: More than one lakh samples tested every day, says ICMR

    Sheela Godbole, the National Coordinator of the WHO-India Solidarity Trial and Head of the Division of Epidemiology, ICMR-National AIDS Research Institute said the hydroxychloroquine arm of the Solidarity Trial alone was paused as the Solidarity Data Safety Monitoring Committee reviewed the data.

    "Yesterday, the report of this committee was received and they advised that the trial should be continued as planned. Based on this, the Executive Group has restarted the hydroxychloroquine arm. The world needs strong data from well-conducted randomised controlled clinical trials on the drug for treatment of COVID-19. We are glad that we can begin the hydroxychloroquine arm again," Dr Godbole said.

    Rajesh Kumar Gupta, Additional Director, Pulmonology and Critical Care, Fortis Noida said, "I do not see as a victory or loss for anyone. Anything that is good for people in this pandemic should be seen as a collective good for all. There was a lot of hue and cry after that Lancet study, and now WHO decided to resume trials." "Let us see what outcomes are there, and how can it benefit humankind," he said.

    Besides hydroxychloroquine, three more treatment protocols -- remdesivir, combination of lopinavir and ritonavir, and lopinavir and ritonavir with Interferon beta-1a -- are being evaluated during the clinical trials at selected hospitals in the world.

    The Indian Council of Medical Research (ICMR) in its revised advisory on May 22 recommended use of the drug as a preventive medication for COVID-19 for asymptomatic healthcare workers in non-COVID hospitals and frontline staff on surveillance duty in containment zones and paramilitary/police personnel involved in coronavirus infection related activities.

    The drug is also recommended for all asymptomatic healthcare workers involved in containment and treatment of COVID-19 and household contacts of laboratory confirmed cases. The Union health ministry on March 31 had also recommended use of hydroxychloroquine in combination with azithromycin on COVID-19 patients who are in severe condition requiring ICU management.

    For Daily Alerts
    Get Instant News Updates
    Enable
    x
    Notification Settings X
    Time Settings
    Done
    Clear Notification X
    Do you want to clear all the notifications from your inbox?
    Settings X
    We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more